Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 22.07
0.00 (0.00%)
At close: Jun 3, 2026
Vanta Bioscience Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 18.16 | 19.64 | 97.23 | 62.76 | 96.87 |
Other Revenue | 1.6 | - | - | - | 3.31 |
| 19.76 | 19.64 | 97.23 | 62.76 | 100.18 | |
Revenue Growth (YoY) | 0.63% | -79.81% | 54.93% | -37.35% | -0.33% |
Cost of Revenue | -8.93 | 15.38 | 8.49 | 9.91 | 8.16 |
Gross Profit | 28.68 | 4.25 | 88.74 | 52.85 | 92.03 |
Selling, General & Admin | 6.12 | 32.45 | 50.12 | 47.7 | 33.09 |
Other Operating Expenses | 10.78 | 14.37 | 25.33 | 29.09 | 20.95 |
Operating Expenses | 20.77 | 90.98 | 120.42 | 103.49 | 67.2 |
Operating Income | 7.91 | -86.72 | -31.68 | -50.64 | 24.83 |
Interest Expense | -7.77 | -40.19 | -57.23 | -56.05 | -23.47 |
Interest & Investment Income | - | 0.72 | 0.59 | 0.59 | 0.78 |
Currency Exchange Gain (Loss) | - | 0.35 | -0.16 | 0.09 | 0.15 |
Other Non Operating Income (Expenses) | - | -0.45 | -0.2 | 3.38 | - |
EBT Excluding Unusual Items | 0.14 | -126.29 | -88.69 | -102.63 | 2.28 |
Gain (Loss) on Sale of Assets | - | - | 0.42 | - | - |
Pretax Income | 0.14 | -126.29 | -88.27 | -102.63 | 2.28 |
Income Tax Expense | -0.95 | 6.61 | -2.2 | 1.82 | 0.94 |
Earnings From Continuing Operations | 1.08 | -132.9 | -86.06 | -104.45 | 1.35 |
Minority Interest in Earnings | - | 85.15 | 62.9 | 39.64 | -0.46 |
Net Income | 1.08 | -47.75 | -23.16 | -64.81 | 0.88 |
Net Income to Common | 1.08 | -47.75 | -23.16 | -64.81 | 0.88 |
Net Income Growth | - | - | - | - | -80.38% |
Shares Outstanding (Basic) | 7 | 6 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 7 | 6 | 6 | 6 | 6 |
Shares Change (YoY) | 14.38% | - | - | - | - |
EPS (Basic) | 0.15 | -7.56 | -3.67 | -10.27 | 0.14 |
EPS (Diluted) | 0.15 | -7.56 | -3.67 | -10.27 | 0.14 |
EPS Growth | - | - | - | - | -80.38% |
Free Cash Flow | -120.92 | -91.02 | -7.21 | -293.17 | -119.02 |
Free Cash Flow Per Share | -16.75 | -14.42 | -1.14 | -46.45 | -18.86 |
Gross Margin | 145.17% | 21.67% | 91.27% | 84.21% | 91.86% |
Operating Margin | 40.03% | -441.66% | -32.58% | -80.69% | 24.78% |
Profit Margin | 5.48% | -243.18% | -23.82% | -103.26% | 0.88% |
Free Cash Flow Margin | -611.96% | -463.56% | -7.41% | -467.13% | -118.81% |
EBITDA | 20.21 | -42.57 | 13.29 | -23.94 | 37.99 |
EBITDA Margin | 102.29% | -216.78% | 13.67% | -38.14% | 37.92% |
D&A For EBITDA | 12.3 | 44.16 | 44.97 | 26.7 | 13.16 |
EBIT | 7.91 | -86.72 | -31.68 | -50.64 | 24.83 |
EBIT Margin | 40.03% | - | -32.58% | -80.69% | 24.78% |
Effective Tax Rate | - | - | - | - | 41.03% |
Revenue as Reported | 19.76 | 20.74 | 98.29 | 69.63 | 101.11 |
Advertising Expenses | - | - | - | - | 0.03 |